Mindmed announces business update and anticipated milestones for 2024

New york--(business wire)--mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (the "company" or "mindmed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today provided a corporate update and outlook for 2024. “our strong progress in 2023 culminated in the delivery of statistically and clinically significant topline results for our lead program (mm-120) in our phase 2b study of gad. these positive results reinforce our sci.
MNMD Ratings Summary
MNMD Quant Ranking